The SURPASS-CVOT study is the largest cardiovascular trial ever conducted with tirzepatide. Its results could transform treatment recommendations.
The question of cardiovascular safety for anti-obesity treatments is fundamental. The SURPASS-CVOT (Cardiovascular Outcomes Trial) study was designed to evaluate whether tirzepatide (Mounjaro) reduces the risk of major cardiovascular events in high-risk patients with type 2 diabetes. With over 14,000 participants followed for several years, it is the most ambitious trial in the tirzepatide clinical program.
Why is a Cardiovascular Trial Crucial?
Since the withdrawal of rofecoxib (Vioxx) and rimonabant due to cardiovascular risks, health authorities require evidence of cardiovascular safety for any new metabolic treatment. The FDA and EMA mandate CVOTs for all antidiabetic drugs. For tirzepatide, SURPASS-CVOT goes beyond mere safety by testing for an active cardiovascular benefit.
Semaglutide (Ozempic/Wegovy) has already demonstrated a 20% reduction in cardiovascular events in the SELECT study. Tirzepatide, with its dual GIP/GLP-1 mechanism, could offer even superior protection, but this remains to be demonstrated.
SURPASS-CVOT Design
The study recruits patients with type 2 diabetes and established atherosclerotic cardiovascular disease (history of myocardial infarction, stroke, or peripheral artery disease). The primary endpoint is the MACE-3 (Major Adverse Cardiovascular Events), a composite of: cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.
Participants are randomized to receive tirzepatide (maximum tolerated dose) or dulaglutide (Trulicity), a GLP-1 agonist already demonstrated to be cardioprotective in the REWIND study. This choice of an active comparator rather than a placebo reflects the evolution of ethical standards: it would now be difficult to justify a placebo group in this high-risk population.
Preliminary Results and Expectations
The full results of SURPASS-CVOT are expected in 2026-2027. However, interim data and post-hoc analyses from the SURPASS and SURMOUNT studies provide encouraging signals:
- Reduction in systolic blood pressure of 6 to 8 mmHg
- Improvement in lipid profile: triglycerides -20 to 25%, increase in HDL
- Reduction in inflammation (CRP) of 30 to 40%
- Reduction in visceral and hepatic fat
- Improvement in arterial stiffness
These factors suggest a probable cardiovascular benefit, but only a large-scale randomized trial can confirm it. Experts estimate a 70 to 80% probability that tirzepatide will demonstrate cardiovascular superiority over dulaglutide.
Potential Impact on Recommendations
If SURPASS-CVOT demonstrates a cardiovascular benefit, the implications would be major. Tirzepatide could become the first-line treatment for diabetic patients at cardiovascular risk, surpassing current GLP-1 agonists. Recommendations from the ADA (American Diabetes Association) and EASD (European Association for the Study of Diabetes) would be updated accordingly.
For non-diabetic obese patients, the TRIUMPH-3 study will separately evaluate the cardiovascular benefits of tirzepatide (Zepbound). These two complementary trials could establish tirzepatide as a universal cardioprotective treatment, regardless of diabetic status.
Monitoring cardiovascular parameters is essential for any patient on tirzepatide. The MounjaGO app allows you to track your blood pressure, weight, and symptoms to generate comprehensive reports for your cardiologist. It costs 5€ for life (one-time payment, zero subscription), is a Web app — no installation required, and uses 100% local storage (maximum privacy).
FAQ: SURPASS-CVOT and Cardiovascular Risk
Does Mounjaro already protect the heart?
Available data suggest a cardioprotective effect (reduction in blood pressure, lipids, and inflammation), but formal proof awaits the results of SURPASS-CVOT. Tirzepatide is already authorized and safe for cardiovascular use.
Can Mounjaro be taken after a heart attack?
Yes, under cardiological supervision. Tirzepatide is not contraindicated after a cardiovascular event. On the contrary, the weight loss and metabolic improvement it provides are beneficial in this context.
What is the difference with the SELECT study on semaglutide?
SELECT tested semaglutide vs placebo in non-diabetic obese patients. SURPASS-CVOT tests tirzepatide vs dulaglutide in diabetic patients. These are different populations and comparators, making direct comparison complex.